Legend Biotech grants CEO 1.13M RSUs

Legend Biotech’s CEO received a multi-year RSU award covering 1,131,860 ordinary shares, vesting annually from 2027 to 2029.

Rhea-AI Filing Summary

Legend Biotech Corp (symbol: LEGN) is the issuer of record for a Form 4 filing submitted to the SEC. Zhang Ingrid reported acquisition or exercise transactions in this Form 4 filing.

Legend Biotech Corp (LEGN) reported that Chief Executive Officer Ingrid Zhang received an equity award of 1,131,860 restricted share units (RSUs) on September 15, 2026. Each RSU is a contingent right to one ordinary share, vesting in three equal installments on September 15, 2027, 2028, and 2029, subject to continued service.

All 1,131,860 ordinary shares underlying these RSUs are reported as directly owned after the transaction, and the award was granted at a reported price of $0.00 per share. The company notes that its ordinary shares may be represented by ADSs, with each ADS equal to two ordinary shares.

Insider Trade Summary

Grant/Award: 1,131,860 shares

Grant/Award 1 txn

Insider Zhang Ingrid

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1, F2	1,131,860	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 1,131,860 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of September 15, 2027, September 15, 2028, and September 15, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

RSUs granted: 1,131,860 units Grant price per ordinary share: $0.00 per share Shares held after transaction: 1,131,860 ordinary shares +1 more

4 metrics

RSUs granted 1,131,860 units Restricted share units granted to the CEO on September 15, 2026

Grant price per ordinary share $0.00 per share Reported price for the 1,131,860 RSUs awarded

Shares held after transaction 1,131,860 ordinary shares Direct holdings reported for the CEO following the RSU grant

ADS to ordinary share ratio 1 ADS : 2 ordinary shares Each American Depositary Share represents two ordinary shares

Key Terms

American Depositary Shares, restricted share units, contingent right

3 terms

American Depositary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted share units financial

"Represents restricted share units ("RSUs"). Each RSU represents a contingent right"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"Each RSU represents a contingent right to receive one ordinary share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Legend Biotech (LEGN) grant to CEO Ingrid Zhang?

Legend Biotech granted CEO Ingrid Zhang 1,131,860 restricted share units (RSUs) on September 15, 2026. Each RSU represents a contingent right to receive one ordinary share of the company upon settlement, subject to vesting and continued service conditions.

How do the RSUs granted to the Legend Biotech (LEGN) CEO vest?

The 1,131,860 RSUs granted to the Legend Biotech CEO vest in three equal installments. One-third vests on each of September 15, 2027, September 15, 2028, and September 15, 2029, subject to the CEO’s continued service to the company on each vesting date.

What is the reported grant price of the RSUs in the Legend Biotech (LEGN) Form 4?

The Form 4 reports a grant price of $0.00 per ordinary share for the 1,131,860 RSUs awarded to the Legend Biotech CEO. This reflects a compensation grant rather than a market purchase of shares.

How many Legend Biotech (LEGN) ordinary shares does the CEO hold after this RSU grant?

Following the RSU grant, the Form 4 reports the CEO as directly holding 1,131,860 ordinary shares (the shares underlying the RSUs) after the transaction. This entire amount is associated with the new award reported on September 15, 2026.

How are Legend Biotech (LEGN) ordinary shares related to its American Depositary Shares (ADSs)?

Legend Biotech discloses that its ordinary shares may be represented by American Depositary Shares. Each ADS represents two ordinary shares of the company, providing an equivalent interest in its equity through ADSs.

Was the Legend Biotech (LEGN) CEO’s RSU grant made under a Rule 10b5-1 trading plan?

The Form 4 indicates the document-level Rule 10b5-1 checkbox as not checked, and there is no footnote stating that the RSU grant was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:19 PM Accepted by SEC EDGAR 09/16/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhang Ingrid

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

77 CORPORATE DRIVE, 4TH FLOOR

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/15/2026		A		1,131,860(2)	A	$0	1,131,860	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of September 15, 2027, September 15, 2028, and September 15, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Robert Staloff, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)